Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate
MetadataShow full item record
We describe the construction and immunobiological properties of a novel whooping cough vaccine candidate, in which the aroQ gene, encoding 3-dehydroquinase, wasdeleted by insertional inactivation using the kanamycin resistance gene cassette and allelic exchange using a Bordetella suicide vector. The aroQ B. pertussis mutant required supplementation of media to grow but failed to grow on an unsupplemented medium. The aroQ B. pertussis mutant was undetectable in the trachea and lungs of mice at days 6 and 12 post-infection, respectively. Antigen-specific antibody isotypes IgG1 and IgG2a, were produced, and cell-mediated immunity [CMI], using interleukin-2 and interferon-gamma as indirect indicators, was induced in mice vaccinated with the aroQ B. pertussis vaccine candidate, which were substantially enhanced upon second exposure to virulent B. pertussis. Interleukin-12 was also produced in the aroQ B. pertussis-vaccinated mice. On the other hand, neither IgG2a nor CMI-indicator cytokines were produced in DTaP-vaccinated mice, although the CMI-indicator cytokines became detectable post-challenge with virulent B. pertussis. Intranasal immunization with one dose of the aroQ B. pertussis mutant protected vaccinated mice against an intranasal challenge infection, with no pathogen being detected in the lungs of immunized mice by day 7 post-challenge. B. pertussis aroQ thus constitutes a safe, non-reverting, metabolite-deficient vaccine candidate that induces both humoral and cellmediated immune responses with potential for use as a single-dose vaccine in adolescents and adults, in the first instance, with a view to disrupting the transmission cycle of whooping cough to infants and the community.
Showing items related by title, author, creator and subject.
Finding the ‘Who’ in Whooping Cough: Vaccinated Siblings are Important Pertussis Sources in Infants 6 Months of Age and UnderBertilone, C.; Wallace, T.; Selvey, Linda (2014)Objectives: To describe the epidemiology of pertussis, and to identify changes in the source of pertussis in infants 6 months of age and under, during the 2008–2012 epidemic in south metropolitan Perth. Design and setting: ...
Mukkur, Trilochan; Richmond, P. (2013)Bordetella pertussis, the aetiological agent of an acute upper respiratory tract disease of humans, “whooping cough”, can infect all age groups with adolescents and adults acting as major source of transmission of this ...
Live Metabolite-Deficient Bordetella pertussis: Determination of Suitability for use as a Vaccine in Humans using the Pertussis Mouse ModelAlhashmi, Ibrahim (2012)This thesis embodies research that has demonstrated that there is strong case for further development of novel live attenuated metabolite deficient B pertussis vaccine such that it is non-toxic because it polarises the ...